260 related articles for article (PubMed ID: 21659625)
1. An improved model for disease progression in patients from the Alzheimer's disease neuroimaging initiative.
Samtani MN; Farnum M; Lobanov V; Yang E; Raghavan N; Dibernardo A; Narayan V;
J Clin Pharmacol; 2012 May; 52(5):629-44. PubMed ID: 21659625
[TBL] [Abstract][Full Text] [Related]
2. Utility of combinations of biomarkers, cognitive markers, and risk factors to predict conversion from mild cognitive impairment to Alzheimer disease in patients in the Alzheimer's disease neuroimaging initiative.
Gomar JJ; Bobes-Bascaran MT; Conejero-Goldberg C; Davies P; Goldberg TE;
Arch Gen Psychiatry; 2011 Sep; 68(9):961-9. PubMed ID: 21893661
[TBL] [Abstract][Full Text] [Related]
3. Disease progression model for cognitive deterioration from Alzheimer's Disease Neuroimaging Initiative database.
Ito K; Corrigan B; Zhao Q; French J; Miller R; Soares H; Katz E; Nicholas T; Billing B; Anziano R; Fullerton T;
Alzheimers Dement; 2011 Mar; 7(2):151-60. PubMed ID: 20810324
[TBL] [Abstract][Full Text] [Related]
4. Clinical predictors of progression to Alzheimer disease in amnestic mild cognitive impairment.
Fleisher AS; Sowell BB; Taylor C; Gamst AC; Petersen RC; Thal LJ;
Neurology; 2007 May; 68(19):1588-95. PubMed ID: 17287448
[TBL] [Abstract][Full Text] [Related]
5. Dynamics of brain structure and cognitive function in the Alzheimer's disease neuroimaging initiative.
Song X; Mitnitski A; Zhang N; Chen W; Rockwood K;
J Neurol Neurosurg Psychiatry; 2013 Jan; 84(1):71-8. PubMed ID: 23123510
[TBL] [Abstract][Full Text] [Related]
6. Predicting Alzheimer's disease development: a comparison of cognitive criteria and associated neuroimaging biomarkers.
Callahan BL; Ramirez J; Berezuk C; Duchesne S; Black SE;
Alzheimers Res Ther; 2015 Nov; 7(1):68. PubMed ID: 26537709
[TBL] [Abstract][Full Text] [Related]
7. Volumetric MRI vs clinical predictors of Alzheimer disease in mild cognitive impairment.
Fleisher AS; Sun S; Taylor C; Ward CP; Gamst AC; Petersen RC; Jack CR; Aisen PS; Thal LJ
Neurology; 2008 Jan; 70(3):191-9. PubMed ID: 18195264
[TBL] [Abstract][Full Text] [Related]
8. Quantification of disease progression and dropout for Alzheimer's disease.
William-Faltaos D; Chen Y; Wang Y; Gobburu J; Zhu H
Int J Clin Pharmacol Ther; 2013 Feb; 51(2):120-31. PubMed ID: 23211395
[TBL] [Abstract][Full Text] [Related]
9. Modeling Alzheimer's disease progression using the disease system analysis approach.
Gomeni R; Simeoni M; Zvartau-Hind M; Irizarry MC; Austin D; Gold M
Alzheimers Dement; 2012 Jan; 8(1):39-50. PubMed ID: 21782528
[TBL] [Abstract][Full Text] [Related]
10. Circulating cholesterol levels, apolipoprotein E genotype and dementia severity influence the benefit of atorvastatin treatment in Alzheimer's disease: results of the Alzheimer's Disease Cholesterol-Lowering Treatment (ADCLT) trial.
Sparks DL; Connor DJ; Sabbagh MN; Petersen RB; Lopez J; Browne P
Acta Neurol Scand Suppl; 2006; 185():3-7. PubMed ID: 16866904
[TBL] [Abstract][Full Text] [Related]
11. Disease progression model in subjects with mild cognitive impairment from the Alzheimer's disease neuroimaging initiative: CSF biomarkers predict population subtypes.
Samtani MN; Raghavan N; Shi Y; Novak G; Farnum M; Lobanov V; Schultz T; Yang E; DiBernardo A; Narayan VA;
Br J Clin Pharmacol; 2013 Jan; 75(1):146-61. PubMed ID: 22534009
[TBL] [Abstract][Full Text] [Related]
12. Clinical trials in Alzheimer's disease. Calculating Alzheimer's Disease Assessment Scale-cognitive subsection with the data from the consortium to establish a registry for Alzheimer's disease.
Gillen TE; Gregg KM; Yuan H; Kurth MC; Krishnan KR
Psychopharmacol Bull; 2001; 35(2):83-96. PubMed ID: 12397889
[TBL] [Abstract][Full Text] [Related]
13. Derivation of a new ADAS-cog composite using tree-based multivariate analysis: prediction of conversion from mild cognitive impairment to Alzheimer disease.
Llano DA; Laforet G; Devanarayan V;
Alzheimer Dis Assoc Disord; 2011; 25(1):73-84. PubMed ID: 20847637
[TBL] [Abstract][Full Text] [Related]
14. Low plasma ApoE levels are associated with smaller hippocampal size in the Alzheimer's disease neuroimaging initiative cohort.
Teng E; Chow N; Hwang KS; Thompson PM; Gylys KH; Cole GM; Jack CR; Shaw LM; Trojanowski JQ; Soares HD; Weiner MW; Apostolova LG;
Dement Geriatr Cogn Disord; 2015; 39(3-4):154-66. PubMed ID: 25547651
[TBL] [Abstract][Full Text] [Related]
15. Disease progression meta-analysis model in Alzheimer's disease.
Ito K; Ahadieh S; Corrigan B; French J; Fullerton T; Tensfeldt T;
Alzheimers Dement; 2010 Jan; 6(1):39-53. PubMed ID: 19592311
[TBL] [Abstract][Full Text] [Related]
16. Lack of reliable evidence for a distinctive ε4-related cognitive phenotype that is independent from clinical diagnostic status: findings from the Australian Imaging, Biomarkers and Lifestyle Study.
Foster JK; Albrecht MA; Savage G; Lautenschlager NT; Ellis KA; Maruff P; Szoeke C; Taddei K; Martins R; Masters CL; Ames D;
Brain; 2013 Jul; 136(Pt 7):2201-16. PubMed ID: 23737466
[TBL] [Abstract][Full Text] [Related]
17. Apolipoprotein E epsilon4 allele is unrelated to cognitive or functional decline in Alzheimer's disease: retrospective and prospective analysis.
Kleiman T; Zdanys K; Black B; Rightmer T; Grey M; Garman K; Macavoy M; Gelernter J; van Dyck C
Dement Geriatr Cogn Disord; 2006; 22(1):73-82. PubMed ID: 16699282
[TBL] [Abstract][Full Text] [Related]
18. Disease progression model for Clinical Dementia Rating-Sum of Boxes in mild cognitive impairment and Alzheimer's subjects from the Alzheimer's Disease Neuroimaging Initiative.
Samtani MN; Raghavan N; Novak G; Nandy P; Narayan VA
Neuropsychiatr Dis Treat; 2014; 10():929-52. PubMed ID: 24926196
[TBL] [Abstract][Full Text] [Related]
19. APOE alleles predict the rate of cognitive decline in Alzheimer disease: a nonlinear model.
Martins CA; Oulhaj A; de Jager CA; Williams JH
Neurology; 2005 Dec; 65(12):1888-93. PubMed ID: 16380608
[TBL] [Abstract][Full Text] [Related]
20. Entorhinal cortex thickness predicts cognitive decline in Alzheimer's disease.
Velayudhan L; Proitsi P; Westman E; Muehlboeck JS; Mecocci P; Vellas B; Tsolaki M; Kłoszewska I; Soininen H; Spenger C; Hodges A; Powell J; Lovestone S; Simmons A;
J Alzheimers Dis; 2013; 33(3):755-66. PubMed ID: 23047370
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
